Clarus Therapeutics

Clarus Therapeutics company information, Employees & Contact Information

Clarus Therapeutics, Inc. is a men's specialty pharmaceutical company with a mission to help men with hypogonadism, a condition associated with a deficiency or absence of endogenous testosterone. We are working hard every day to make a difference in the lives of affected men. As a privately-held company, Clarus Therapeutics is backed by Thomas, McNerney & Partners, L.P., H.I.G. BioHealth Partners, ProQuest Investments, C-Bridge Capital Partners, LLC, BVCF Management, Ltd. and Pavilion Capital Pte Ltd. To learn more, visit clarustherapeutics.com. View our community guidelines: http://bit.ly/2H9QmH5

Company Details

Employees
15
Founded
-
Address
Northbrook, Il
Phone
847-562-4300
Email
ad****@****ics.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Northbrook, IL
Looking for a particular Clarus Therapeutics employee's phone or email?

Clarus Therapeutics Questions

News

Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder - Yahoo Finance

Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder Yahoo Finance

New Oral Tx Approved for Males With Certain Types of Hypogonadism - Renal and Urology News

New Oral Tx Approved for Males With Certain Types of Hypogonadism Renal and Urology News

Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer - PR Newswire

Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer PR Newswire

Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering - GlobeNewswire

Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering GlobeNewswire

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate) - Yahoo Finance

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate) Yahoo Finance

Clarus Therapeutics Closes Transaction With Blue Water, - GlobeNewswire

Clarus Therapeutics Closes Transaction With Blue Water, GlobeNewswire

Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer - Yahoo Finance

Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer Yahoo Finance

Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to Patients - GlobeNewswire

Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to Patients GlobeNewswire

Clarus Therapeutics Receives U.S. FDA Approval of JATENZO® - GlobeNewswire

Clarus Therapeutics Receives U.S. FDA Approval of JATENZO® GlobeNewswire

Clarus Therapeutics Announces Commercial Launch and - GlobeNewswire

Clarus Therapeutics Announces Commercial Launch and GlobeNewswire

Top Clarus Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant